Ventyx Biosciences (NASDAQ:VTYX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Ventyx Biosciences (NASDAQ:VTYX) had its target price boosted by research analysts at Wells Fargo & Company from $11.00 to $14.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 59.64% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer increased their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Ventyx Biosciences Stock Down 5.3%

Shares of VTYX stock traded down $0.49 on Friday, reaching $8.77. The stock had a trading volume of 2,638,338 shares, compared to its average volume of 2,134,669. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $9.50. The firm has a market capitalization of $625.39 million, a price-to-earnings ratio of -5.22 and a beta of 1.23. The firm’s 50-day moving average is $4.08 and its two-hundred day moving average is $2.85.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. On average, sell-side analysts forecast that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

A number of institutional investors have recently bought and sold shares of VTYX. Hudson Bay Capital Management LP bought a new position in shares of Ventyx Biosciences during the second quarter worth approximately $34,000. Pallas Capital Advisors LLC acquired a new stake in Ventyx Biosciences during the second quarter worth approximately $38,000. Engineers Gate Manager LP acquired a new stake in Ventyx Biosciences during the second quarter worth approximately $42,000. Wealth Enhancement Advisory Services LLC bought a new position in Ventyx Biosciences during the 1st quarter worth $28,000. Finally, Jump Financial LLC acquired a new position in Ventyx Biosciences in the 2nd quarter valued at $53,000. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.